Please turn JavaScript on
Find more feeds
Endpoints News icon

Endpoints News

Click on the "Follow" button below and you'll get the latest news from Endpoints News via email, mobile or you can read them on your personal news page on this site.

You can unsubscribe anytime you want easily.

You can also choose the topics or keywords that you're interested in, so you receive only what you want.

Endpoints News title: Endpoints News – Biotech and pharma business news, with a focus on the science, people and money that drive the industry.

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  7.24 / day

Message History

Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut
A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million combined. Seaport Therapeutics, Hemab Therapeutics and Avalyn Pharma are the ...

Read full story
J&J axes pair of CAR-T therapies for lymphoma, citing evolving market
Johnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and antibody-based drugs addressing the disease. The drugmaker

Read full story
Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit
→ Boehringer Ingelheim has brought in Christie Bloomquist as SVP, corporate affairs, US human pharma, and she’ll be president of the Boehringer Cares Foundation. Peer Review informed you about her move to ...

Read full story
FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
In its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn't show a “clinically meaningful” benefit. AstraZeneca touted ...

Read full story
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated approval in 2024 in this setting. But a Phase ...

Read full story